Skip to main content

Texas Medicaid Now Participates in the Cell and Gene Therapy Access Model

Last updated on

On September 1, 2025, Texas Medicaid began to use the Cell and Gene Therapy (CGT) Access Model that was implemented by the Centers for Medicare & Medicaid Services (CMS) Innovation Center.

The CGT Access Model focuses on the following gene therapies for sickle cell disease:

  • Lyfgenia by bluebird bio
  • Casgevy by Vertex Pharmaceuticals

These therapies involve the use of chemotherapy and may affect the client’s fertility. The model offers clients access to fertility preservation services that would not otherwise be covered by Texas Medicaid. The drug manufacturers will cover the cost of these services.

Providers can find more information about gene therapies, eligibility, claims submission, and more on the Texas Vendor Drug Program website.

Email vdp-policy@hhs.texas.gov with comments or questions.